



Media Contact
Carol Berry
Chief Business Officer, SVP
Caprion
cberry@caprion.com
514.360.3600

Caprion to Present “Identification and Quantification of Host Cell Proteins by LC-MS/MS and LC-MRM”

2015 Host Cell Protein Workshop by BEBPA, May 14-15

Montreal, Canada – May 13, 2015—Caprion announced today it will present data on the application of mass spectrometry for identification and quantification of host cell proteins (HCP) that copurify with biologics. A case study will be presented utilizing the ProteoCarta™ technology platform to show how proteins can be detected without antibodies or gel separation after manufacturing in CHO, E. coli, and yeast. The method will be described for discovery of proteins including two orthogonal methods to ensure good coverage. This approach can be used directly to compare purity of different batches, monitor batch uniformity, or compare different production sites. The assay can be further refined by developing a targeted multiple reaction monitoring (MRM) assay to quantify hundreds of peptide/protein of interest.

Martin LeBlanc, President and CEO of Caprion said, “We are excited to showcase our recent results and advancements in the detection of host cell proteins for biologic manufacturing processes using our ProteoCarta Platform. The industry and the FDA realize that the established standard of using antibody-based assays may not be detecting all of the host cell proteins remaining in a final therapeutic product. We believe that mass spectrometry methods like ProteoCarta may represent viable complementary approaches to enable more comprehensive detect and monitor such host cell protein impurities.”

Presentation Title:

Identification and Quantification of Host Cell Proteins by LC-MS/MS and LC-MRM

Speaker: Daniel Chelsky, Ph.D., Chief Scientific Officer, Caprion

Time: Wednesday, May 15, 11:30 AM

Place: Sheraton’s Fisherman’s Wharf, San Francisco, CA

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta®, offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion’s proteomics business unit, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50

major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.